OPKO Health, Inc.
$1.55B- Market cap
- $1.22B
- Debt
- +$687.93M
- Cash
- −$364.41M
Capital structure 64% equity / 36% debt · EV / Revenue 2.55x
Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
FY 2025 ·
Decision snapshot: OPK stock price near parity vs FLGT $1.64 current versus $1.37 implied using P/S multiple.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at FLGT's multiple
Implied fair value · at OPK's multiple
Snapshot Sep 4, 4:00 PM ET
Metric by metric
Where each company leads, and how wide the gap is.
Growth lag
Pricing power
Operating leverage
Multiple premium
Not comparable
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: OPK FY 2025 (ended Dec 31, 2025) · FLGT FY 2025 (ended Dec 31, 2025).
Trendline
Six fiscal years of revenue, earnings, and margins before underwriting a re-rating.
Price framework
Market cap plus debt, less cash.
Capital structure 64% equity / 36% debt · EV / Revenue 2.55x
Capital structure 100% equity / 0% debt · EV / Revenue 1.53x
OPK carries the larger enterprise value at $1.55B against $493.16M; FLGT trades on the lower EV / Revenue multiple (1.53x vs 2.55x).
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
OPKO Health, Inc. · implied price per share
Latest annual free cash flow must be positive to qualify the filing-backed baseline.
FULGENT GENETICS, INC. · implied price per share
Latest annual free cash flow must be positive to qualify the filing-backed baseline.
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Debt / equity
Total debt against shareholders' equity
0.54x
0.00x
Net debt / EBITDA
Leverage against operating earnings
-3.03x
1.15x
Cash and equivalents
Liquid reserves on the balance sheet
$364.41M
$50.19M
Total debt
Interest-bearing obligations outstanding
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
AMARIN CORP PLC\UK
OPK vs AMRN
Sarepta Therapeutics, Inc.
OPK vs SRPT
Amphastar Pharmaceuticals, Inc.
OPK vs AMPH
SUPERNUS PHARMACEUTICALS, INC.
OPK vs SUPN
Harmony Biosciences Holdings, Inc.
OPK vs HRMY
NEOGENOMICS INC
OPK vs NEO
Natera, Inc.
OPK vs NTRA
Guardant Health, Inc.
OPK vs GH
EXACT SCIENCES CORP
OPK vs EXAS
$687.93M
$476.00K
LLM-powered synthesis
An on-demand narrative read of the same deterministic data.
The deterministic comparison remains available. Sign in when you want an on-demand narrative synthesis of the same data.